DeciBio’s Post

🎉 Celebrating 19 Years of Axendia: A Journey of Trust & Innovation 🚀 -Daniel R. Matlis, President & Founder, Axendia, Inc. Nineteen years ago, we founded Axendia with a simple but powerful goal: to provide life sciences executives, technology companies, and regulators with strategic, actionable insights grounded in a deep understanding of our industry’s complexities. Since then, we've remained dedicated to that vision, consistently offering trusted advice that goes beyond buzzwords, trends, and jargon.  We’re proud to have earned your trust along the way, becoming a valued partner in helping your organization navigate the intersection of business, technology, and regulatory domains. As we mark this milestone, it’s clear that the future is already taking shape, and we are privileged to be part of it. Technologies like artificial intelligence, machine learning, and quantum computing are transforming the life sciences landscape, and we remain committed to helping you integrate these advancements in ways that enhance decision-making and improve patient outcomes. However, none of this would have been possible without the trust and confidence of our clients, collaborators, and my fellow Axendians. You have been essential to our journey, and for that, we are deeply grateful.  Your continued support has driven our growth and success, and we look forward to the opportunity to keep providing you with actionable insights. As we enter our 20th year, we are excited about what lies ahead. Together, we will continue shaping the future of life sciences, and for that, we are grateful. https://lnkd.in/e_5PnEM9 Sandra Rodriguez Daniel Matlis Kelly Doering Thomas Maeder Eric M. Luyer Ellyn McMullin Robyn Barnes Giselle C. Matlis Jared Matlis Jordan A. Matlis Mónica V. M. David Lennard

This important collaboration employs Citeline’s data mastering, subject matter expertise, and technology capabilities to augment its gold standard historical site data, as well as create new predictive algorithms, with the support of Greenphire’s data. As Citeline applies its expertise in data science, analytics and product development to these datasets, it establishes differentiating capabilities not found elsewhere in the market and the opportunity to deploy innovative tools for making more effective, predictive clinical trial decisions. Site level performance data, site capabilities, patient/site burden, budget implications.....the list is endless! #Citeline #Greenphire #AI #ClinicalTrials #Predictive

Keep the conversation going from the #Biotech CEO Summit! One of the major takeaways is the growing importance of an Integrated Evidence Generation approach, where medical value is created faster by connecting diverse topics, fields and experiences, rather than considering them in isolation (or opposition). The art of product development is about merging perspectives of all stakeholders – patients, physicians, and payers – and combining them into an integrated research, clinical, and real world/commercial plan. Connect with our EVP of Biopharma Joris Pezzini to continue the discussion or visit our dedicated biotech page: https://lnkd.in/dVAEZRKN. We’d love to help you meet your development and funding goals!

I'm thrilled to invite you all to join us on May 29th for a captivating Panel Discussion on a topic that's dear to my heart: "Scaling to the Clinic: Strategies for Evaluating Lab Resourcing Solutions for R&D." Teaming up with SmartLabs, we're bringing together a stellar lineup of industry leaders to explore the core challenges and opportunities in the biopharma sector. As the Founder of 🧬US Lab Partners LLC🧬, I'm honored to moderate this discussion alongside esteemed panelists: 🧬 Angela Hui, VP of Operations, Elektrofi 🧬 John Maynes, Associate Director of Lab Operations, Prime Medicine, Inc. 🧬 Christian Lawrence, Site Director, SmartLabs 🧬 Michael Magliochetti, Operating Partner, Riverside Partners 🧬 Brian Gallagher, Jr., Managing Partner and Co-Founder, Trekk Venture Partners In today's dynamic biopharma landscape, effectively managing resources is key to driving innovation and advancing critical therapies. Whether you're a startup striving to maximize runway or a larger company navigating the complexities of asset development, this discussion promises invaluable insights. Join us for an engaging dialogue where we'll explore how industry leaders are navigating the ever-changing terrain of R&D resourcing. Let's come together to inspire, learn, and drive meaningful change in the biopharma industry. RSVP now via the link in the comments and mark your calendars for an event you won't want to miss! See you there! 🧬🔬 #Biopharma #R&D #LabResourcing #Innovation #PanelDiscussion

The wait is over! Fierce Biotech Fierce 15 is here! Nominations starting today in search of the best and brightest in biotech.  Send in your suggestions for the fiercest companies in the game now! 👉 https://lnkd.in/eMqebHWa 📢 Follow Fierce Life Sciences Events for the latest news and updates #FierceBiotech #FiercePharma #Fierce15

What is new in the news? Read below Citeline Citeline Clinical Greenphire

Join us on May 29th for a Panel Discussion: "Scaling to the Clinic: Strategies for evaluating the right lab resourcing solution for your R&D efforts." We're pleased to co-host this event with SmartLabs. RSVP via the link in the comments below. The panel will be moderated by US Lab Partners LLC Founder Demet Aybar and will feature panelists: Angela Hui, VP of Operations, Elektrofi John Maynes, Associate Director of Lab Operations, Prime Medicine, Inc. Christian Lawrence, Site Director, SmartLabs Michael Magliochetti, Operating Partner, Riverside Partners Brian Gallagher, Jr., Managing Partner and Co-Founder, Trekk Venture Partners Volatile conditions in the biopharma funding market and the rise of novel therapies make it imperative that a company’s operating strategies be managed in a way that successfully shepherd assets forward in a cost-efficient manner. For start-up companies with one or two assets, stretching runway to reach the next milestone is top of mind when satisfying investors and securing additional investment. Midsize and larger companies must also marshal resources strategically in their race to get assets into the clinic in a hypercompetitive research environment. Companies can choose to outsource, insource, or defer costs at every stage of R&D and across dozens of different workflows. During this interactive discussion, hear how leaders pursuing novel therapies are weighing their strategies for resourcing to support great science while meeting the practical and economic considerations of R&D. #biopharma #funding #R&D #operations #science

Microbiologics Welcomes SensID! Microbiologics is excited to announce the addition of SensID, a leader in oncology and precision medicine diagnostics based in Rostock, Germany. This partnership strengthens their mission to advance global healthcare by combining SensID’s expertise with their commitment to quality control in diagnostics. Together, they will support technology developers and healthcare professionals to improve patient care worldwide. Congratulations Microbiologics, Granite Partners, Lathrop GPM LLP, and CLA (CliftonLarsonAllen), all corporate-level investors in the GSDC, for their role in this successful partnership! #HealthcareInnovation #BiotechPartnership #AdvancingHealthcare

"Charles River’s work with Ori is part of a larger commitment to improve and scale advanced therapies through the adoption of cutting-edge closed and automated platforms to meet the growing patient demand for life-saving therapies. The test of Ori’s new IRO platform using head-to-head process transfer runs shows promising results and provides therapeutic developers another option for manufacturing and helps to address the manufacturing bottleneck challenge.” - Matthew Hewitt, Vice President, CTO Manufacturing Business Division at Charles River Laboratories We recently presented new data from our ongoing collaboration with Charles River Laboratories, where Jason C. Foster highlighted IRO®’s ability to reduce cost of goods by up to 50% and cut production time by up to 25%. When compared to a legacy manufacturing technology, IRO not only delivered higher CAR+ cell yields in less time, but also streamlined workflows and enhanced biological performance – all of which were demonstrated live at our 'Experience IRO' event in Boston. By Automating Better Biology™, the IRO platform empowers therapy developers to scale their impact with efficient, standardized manufacturing processes. A huge thank you to the team at Charles River and to everyone who joined us in Boston. If you missed out, don’t worry – schedule your 1:1 demo to see IRO in action ➡️ https://lnkd.in/eXEXEGZZ Read more about our collaboration ➡️ https://lnkd.in/e5gT-zXz #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🌟 Big news for Citeline! 🌟 We’re thrilled about our new partnership with Greenphire, a game-changer for how we build the next generation of our products! 🚀 With Greenphire’s proprietary financial data, we’re boosting our expert insights and unlocking even deeper clinical trial, site, and investigator performance data (and much more!) 📊 Combine that with Citeline’s data mastery, tech capabilities, and predictive algorithms – and we’re taking our best-in-class datasets to incredible new heights! 🙌✨ This means even better insights and recommendations for our clients. Stay tuned for more updates on how we’re integrating Greenphire’s data into our products. Exciting things are on the way! 👀🔍 #Partnership #Innovation #DataDriven #ClinicalTrials #PharmaInsights #Citeline